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Introduction

Methods Cont.

□ Osteoporosis is a common disease of the bones that is characterized by
a decrease in bone density and bone strength, resulting in bone
fragility.1

□ Patients exhibiting moderate to high risk for developing osteoporosis
based on their SCORE result will be offered BMD screening using a
portable heel ultrasound densitometer (Hologic Sahara Bone
Densitometer), which will determine T-scores. There will be no additional
cost to patients for participating in this study.

□ In the United States, approximately 44 million people have low bone
density, 10 million of whom have osteoporosis and 34 million with
osteopenia.2 This equates to about 55% of the U.S. population aged 50
years and older. The number of people with osteoporosis-related
fractures is predicted to increase dramatically due to the aging
population of the country.2
□ Osteoporotic bone fractures are responsible for pain, decreased quality
of life, lost workdays, and disability.
□ It is important to identify and test patients at high risk for developing
osteoporosis, as well as implement strategies to help prevent or delay
the onset of this disease.
□ Pharmacists play a critical role in our healthcare system since they are
easily accessible in the community.

Objectives
□ To develop and implement models pharmacists can utilize in a
community pharmacy setting to test and identify patients at risk for
osteoporosis.
□ To determine the feasibility of implementing this model in additional
community pharmacy locations.

Methods
□ Patients will be recruited through a computer-generated report
identifying females aged 50 years or older and females 18 years or
older and taking medications (Table 1) that lower bone density. These
patients must have filled a prescription at the community pharmacy
within the past 6 months.
□ Patients presenting to the pharmacy with identified risk factors will also
be offered screening.
□ The Simple Calculated Osteoporosis Risk Estimation (SCORE) risk
assessment tool will be completed on the patients to identify their risk
for developing osteoporosis. This tool was selected because it has
been validated in women in multiple studies for predicting low bone
mineral density (BMD) and osteoporotic fracture.

□ Those patients with 2 risk factors for osteoporosis and a T-score below
-1.0 or those patients with 0-1 risk factors and a T-score below -2.0 will
be referred to their physician for dual-energy x-ray absorptiometry and/or
pharmacotherapy.

Results
□ Data collection period is expected to last for four months, starting from
December 2014 to March 2015. To date, no patients have been tested
for osteoporosis.
□ Initial computer-generated report identified 41 females aged 18 years
and older on medications that lower bone density.
□ Second computer-generated report identified 528 females aged 50
years and older.
□ Descriptive statistics will be used to assess data.

□ Every patient that completes the BMD screening will be offered
personalized consultation on osteoporosis by a pharmacist. At 6 to 8
weeks after BMD screening, patients will be contacted by telephone for
follow-up on physician referral, as well as any behaviors initiated and/or
medications modified.

□ Exclusion of males from the study protocol may not be representative of
the general population.

□ Inclusion Criteria: females 50 years or older and females 18 years of
age and older and taking medications that lower bone density (Table 1).

□ Travel distance may prevent identified patients from participating in the
study.

□ Exclusion Criteria: Males, patients under the age of 18, females who
are pregnant, patients whose skin is abraded and/or have an open sore
in the area that comes in contact with the system, patients who have
received a dual-energy x-ray absorptiometry in the past 2 years.

□ Although the counseling information is standardized, differences in
pharmacists’ consultation techniques may lead to variations in
information presented to patients.

□ Data Collection: Patient demographic information survey (including
education level, yearly household income and amount willing to pay for
BMD test), SCORE risk assessment results, and T-scores from BMD
readings. The entire amount of time a pharmacist would need to perform
the duties from screening to counseling will also be recorded.

Limitations

Implications
□ The results of this project will help to determine the role of pharmacists
in osteoporosis testing in healthcare settings.
□ Patients’ awareness of osteoporosis, including preventive and treatment
options, will increase.

□ The study protocol has been approved by the university IRB committee.
Table 1: Medications Associated With Osteoporosis1

□ This project will determine whether this program model can be
implemented in other community pharmacy locations.

Anticoagulants (heparin, warfarin, LMWH: dalteparin, enoxaparin)
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Anticonvulsants (carbamazepine, divalproex sodium, gabapentin,
lamotrigine, levetiracetam, oxcarbazepine, phenobarbital,
phenytoin, topiramate, valproic acid)
Cyclosporine A and tacrolimus
Cancer chemotherapy drugs (anastrozole, letrozole, leuprolide)
‘ Glucocorticoids (betamethasone, dexamethasone, hydrocortisone,
methylprednisolone, prednisone, prednisolone, traimacinolone)
Lithium
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